13
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T5354 | IRAK4-IN-7 | CA-4948 | IRAK |
IRAK4-IN-7 (CA-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model. | |||
T8380 | Bendamustine | SDX105 | Apoptosis , Others , DNA Alkylator/Crosslinker |
Bendamustine (SDX105) for the treatment of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia | |||
T9924 | Obinutuzumab | Obinutuzumab/afutuzumab | Others |
Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma. | |||
T35617 | Mitoguazone | MGBG,Methyl-GAG | Apoptosis , HIV Protease |
Mitoguazone (Methyl-GAG) is a selective S-adenosyl-methionine decarboxylase inhibitor that penetrates the blood-brain barrier and disrupts polyamine biosynthesis. Mitoguazone is a synthetic polycarbonyl derivative with a... | |||
T76692 | Mosunetuzumab | BTCT-4465A | Others |
Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to stu... | |||
T40901 | Aderbasib | INCB007839,INCB7839 | |
Aderbasib (INCB007839) is a highly potent and orally active hydroxamate-based inhibitor of ADAM10 and ADAM17, with low nanomolar affinity. This compound demonstrates strong antineoplastic activity and holds potential for... | |||
T78331 | Epcoritamab | GEN3013 | |
Epcoritamab (GEN3013) is a bispecific IgG1 antibody that redirects T-cells toward CD3×CD20-positive tumor cells, inducing potent T-cell-mediated cytotoxicity against B-cell non-Hodgkin lymphoma (NHL) cell lines [1]. | |||
T78686 | Apoptosis inducer 11 | Apoptosis | |
Apoptosis Inducer 11 (compound 3u) promotes apoptosis via the mitochondrial pathway and elicits a G2/M block alongside a marked reduction in the S phase within non-Hodgkin lymphoma cell lines [1]. | |||
T76768 | Pinatuzumab | ||
Pinatuzumab, a CD22 monoclonal antibody, specifically targets the CD22 cell-surface antigen and is utilized in the synthesis of antibody-drug conjugates (ADCs) for researching a range of diseases, including non-Hodgkin l... | |||
T76765 | Veltuzumab | ||
Veltuzumab (IMMU-106), a humanized anti-CD20 monoclonal antibody, exhibits a low EC50 value ranging from 0.08 to 0.09 μg/mL in the Daudi cell line. It is used in cancer research, specifically for non-Hodgkin lymphoma (NH... | |||
T82078 | Iladatuzumab | MCDS0593A | |
Iladatuzumab (MCDS0593A), a humanized IgG1 monoclonal antibody targeting CD79B, serves as a precursor for the synthesis of antibody-drug conjugates (ADCs), such as Iladatuzumab vedotin (DCDS0780A), with potential applica... | |||
T68485 | Apilimod HCl | ||
Apilimod dimesylate is a potent and selective PIKfyve inhibitor. It exhibits no significant activity at other lipid kinases and protein kinases, including PIP4K, PIP5K, mTOR, PI3K and PI4K. Apilimod dimesylate inhibits c... | |||
T73700 | Daunorubicin citrate | ||
Daunorubicin (Daunomycin) citrate, a potent anti-tumor anthracycline antibiotic, acts as a topoisomerase II inhibitor. It effectively inhibits DNA and RNA synthesis, diminishes cancer cell viability, and promotes apoptos... |